Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom]

Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO

Inclusion Criteria:

• Patients with visual impairment secondary to branch retinal vein occlusion (BRVO) with a BCVA between 19 and 73 letters in one eye and at least 35 letters in the other eye.

Exclusion Criteria:

• Pregnant or nursing women or women of child bearing potential without unless using an effective contraception
• Stroke or myocard infarction within 3 months prior to study
• History of malignancy within the past 5 years
• Uncontrolled hypertension
• Active infection or inflammation in any eye
• use of corticosteroids for at least 30 days in the last 6 months
• treatment with anti-angiogenic drugs in any eye within last 3 months
• Panretinal or focal/drid laser photocoagulation within the last few months